CAI
Caris Life Sciences, Inc.
Key Financials
Net Income
$-68088000
↑ 75.8%
Revenue
$812.0M
↑ 97.0%
Operating Income
$45.1M
↑ 117.5%
EPS (Diluted)
$-3.22
↑ 69.8%
Total Assets
$1.1B
↑ 227.5%
Shareholders' Equity
$577.3M
↑ 123.1%
Total Liabilities
$548.4M
↓ 11.7%
Cash & Equivalents
$796.3M
↑ 1145.2%
Recent SEC Filings
| Form Type | Filed Date | Link |
|---|---|---|
| 4 | 5/18/2026 | View on SEC |
| 4 | 5/18/2026 | View on SEC |
| 4 | 5/18/2026 | View on SEC |
| 4 | 5/18/2026 | View on SEC |
| 4 | 5/18/2026 | View on SEC |
| SCHEDULE 13G/A | 5/12/2026 | View on SEC |
| SCHEDULE 13G/A | 5/12/2026 | View on SEC |
| 4 | 5/12/2026 | View on SEC |
| 10-Q | 5/8/2026 | View on SEC |
| 8-K | 5/7/2026 | View on SEC |
Company Information
| Field | Value |
|---|---|
| Ticker | CAI |
| Company Name | Caris Life Sciences, Inc. |
| CIK | 2019410 |
| Sector | Services-Medical Laboratories |
| Industry | Non-accelerated filer Emerging growth company |
| Exchange | Nasdaq |
| SIC Code | 8071 |
| SIC Description | Services-Medical Laboratories |
| Entity Type | operating |
| Fiscal Year End | 1231 |
| State of Incorporation | TX |
| Phone | (866) 771-8946 |